Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data

Riccardo Lencioni, Thierry de Baere, Michael C. Soulen, William S. Rilling, Jean‐Francois H. Geschwind – 13 January 2016 – Transarterial chemoembolization (TACE) using lipiodol‐based regimens, including the administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta‐analyses of randomized, controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of lipiodol TACE in treatment of HCC.

CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors

Ming Liu, Leilei Chen, Ning‐Fang Ma, Raymond Kwok Kei Chow, Yan Li, Yangyang Song, Tim Hon Man Chan, Shuo Fang, Xiaodong Yang, Shaoyan Xi, Lingxi Jiang, Yun Li, Ting‐Ting Zeng, Yan Li, Yun‐Fei Yuan, Xin‐Yuan Guan – 11 January 2016 – High‐grade tumors with poor differentiation usually show phenotypic resemblance to their developmental ancestral cells. Cancer cells that gain lineage precursor cell properties usually hijack developmental signaling pathways to promote tumor malignant progression. However, the molecular mechanisms underlying this process remain unclear.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Fred Poordad, Eugene R. Schiff, John M. Vierling, Charles Landis, Robert J. Fontana, Rong Yang, Fiona McPhee, Eric A. Hughes, Stephanie Noviello, Eugene S. Swenson – 11 January 2016 – Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver transplantation recurrence represents a high unmet medical need with no approved therapies effective across all HCV genotypes.

Canonical NF‐κB signaling in hepatocytes acts as a tumor‐suppressor in hepatitis B virus surface antigen‐driven hepatocellular carcinoma by controlling the unfolded protein response

Yoshiaki Sunami, Marc Ringelhan, Enikö Kokai, Miao Lu, Tracy O'Connor, Anna Lorentzen, Achim Weber, Ann‐Katrin Rodewald, Beat Müllhaupt, Luigi Terracciano, Sarah Gul, Sebastian Wissel, Frank Leithäuser, Daniel Krappmann, Petra Riedl, Daniel Hartmann, Reinhold Schirmbeck, Pavel Strnad, Norbert Hüser, Jörg Kleeff, Helmut Friess, Roland M Schmid, Fabian Geisler, Thomas Wirth, Mathias Heikenwalder – 11 January 2016 – Chronic hepatitis B virus (HBV) infection remains the most common risk factor for hepatocellular carcinoma (HCC).

Subscribe to